




In the Claims:



54. (Currently amended) A compound according to the formula:



Wherein B is

or


;

R is H, F, Cl, Br, I, C<sub>1</sub>-C<sub>4</sub> alkyl, -C≡N, -C≡C-R<sub>a</sub>,  or  ;


X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I;

R<sup>1</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or an ether group;

R<sup>2</sup> is H, an acyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a





or






group;


Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R<sup>8</sup> is H or a C<sub>1</sub>-C<sub>20</sub> alkyl or ether group;

R<sup>3</sup> is a C<sub>1</sub>, C<sub>3</sub> or C<sub>4</sub> alkyl group,  $-(CH_2)_n-C\equiv C-R_a$ ,  or 

when B is  and

R<sup>3</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl,  $-(CH_2)_n-C\equiv C-R_a$ ,  or  when B is



R<sup>3a</sup> and R<sup>3b</sup> are each independently H, F, Cl, Br and I;

R<sub>a</sub> is H, F, Cl, Br, I, or -C<sub>1</sub>-C<sub>4</sub> alkyl;


Y is H, F, Cl, Br, I or -C<sub>1</sub>-C<sub>4</sub> alkyl; and

k is ~~0, 1 or 2~~ 0-12;


n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.


55. (Currently amended) The compound according to claim 54 wherein B is



56. (Previously Presented) The compound according to claim 55 wherein R<sup>3</sup> is



57. (Previously Presented) The compound according to claim 56 wherein R is F, Cl, Br, I, C<sub>1</sub>-C<sub>3</sub> alkyl,




58. (Previously Presented) The compound according to claim 56 wherein R is CH<sub>3</sub>, R<sup>3</sup> is  $-(CH_2)_n-C\equiv C-R_a$ , n is 0 and R<sub>a</sub> is H.

59. (Previously Presented) The compound according to claim 58 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.

60. (Previously Presented) The compound according to claim 58 wherein R<sup>2</sup> is H.


61. (Previously Presented) The compound according to claim 54 which is



62. (Previously Presented) The compound according to claim 61 wherein  $R^2$  is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.


63. (Previously Presented) The compound according to claim 61 wherein  $R^2$  is H.

64. (Currently amended) The compound according to claim 54 wherein B is




and k is 0, 1 or 2.

65. (Previously Presented) The compound according to claim 64 wherein  $R^3$  is  $CH_3$ ,



66. (Previously Presented) The compound according to claim 65 wherein R is H, F, Cl, Br, I,  $CH_3$ ,





67. (Previously Presented) The compound according to claim 64 wherein R is CH<sub>3</sub>, R<sup>3</sup> is  $-(CH_2)_n-C\equiv C-R_a$ , n is 0 and R<sub>a</sub> is H.

68. (Previously Presented) The compound according to claim 67 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.


69. (Previously Presented) The compound according to claim 68 wherein R<sup>2</sup> is H.

70. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:



Wherein B is


or



;


R is H, F, Cl, Br, I, C<sub>1</sub>-C<sub>4</sub> alkyl, -C≡N, -C≡C-R<sub>a</sub>,

X is H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, Br or I;







$R^1$  is H, an acyl group, a  $C_1-C_{20}$  alkyl or an ether group;

$R^2$  is H, an acyl group, a  $C_1-C_{20}$  alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

$R^8$  is H or a  $C_1-C_{20}$  alkyl or ether group;



$R^{3a}$  and  $R^{3b}$  are each independently H, F, Cl, Br and I;

$R_a$  is H, F, Cl, Br, I, or  $-C_1-C_4$  alkyl;


Y is H, F, Cl, Br, I or  $-C_1-C_4$  alkyl;

k is ~~0, 1 or 2~~ 0-12; and


n is 0, 1, 2, 3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.


71. (Previously Presented) The composition according to claim 70 wherein B is



72. (Previously Presented) The composition according to claim 71 wherein  $R^3$  is



73. (Previously Presented) The composition according to claim 72 wherein R is F, Cl, Br, I,  $C_1-C_3$  alkyl,




74. (Previously Presented) The composition according to claim 71 wherein R is  $\text{CH}_3$ ,  $R^3$  is  $-(CH_2)_n-C\equiv C-R_a$ , n is 0 and  $R_a$  is H.

75. (Previously Presented) The composition according to claim 74 wherein  $R^{3a}$  and  $R^{3b}$  are both H.

76. (Previously Presented) The composition according to claim 75 wherein  $R^2$  is H.


77. (Previously Presented) The composition according to claim 70 wherein said compound is



78. (Previously Presented) The composition according to claim 77 wherein  $R^2$  is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.


79. (Previously Presented) The composition according to claim 77 wherein  $R^2$  is H.

80. (Currently amended) The composition according to claim 70 wherein B is




and k is 0, 1 or 2.

(Previously Presented) The composition according to claim 80 wherein  $R^3$  is  $CH_3$ ,





81. (Previously Presented) The composition according to claim 81 wherein R is H, F, Cl, Br, I, CH<sub>3</sub>,




83. (Previously Presented) The composition according to claim 80 wherein R is CH<sub>3</sub>, R<sup>3</sup> is  $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$ , n is 0 and R<sub>a</sub> is H.

84. (Previously Presented) The composition according to claim 83 wherein R<sup>3a</sup> and R<sup>3b</sup> are both H.

85. (Previously Presented) The composition according to claim 84 wherein R<sup>2</sup> is H.

86. (Previously Presented) The composition according to claim 70 wherein said compound is



Where R<sup>1</sup> is H or an acyl group; and

R<sup>2</sup> is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

87. (Previously Presented) The composition according to claim 86 wherein R<sup>1</sup> is H and R<sup>2</sup> is H.